MedTrace Logo

Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs

NCT02167425 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2015-11-23

No results posted yet for this study

Summary

To improve ART initiation among people who inject drugs, the investigators propose to develop and pilot a multi-component Integrated Methadone and Antiretroviral Therapy strategy (IMAT) in Dar es Salaam, Tanzania. In doing so, the investigators anticipate building a functional model of methadone and ART integration that improves the effectiveness and efficiency of service delivery.

Conditions

  • HIV
  • Opioid Dependence

Interventions

OTHER

IMAT

The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Muhimbili University of Health and Allied Sciences

    collaborator OTHER

  • Pangaea Global AIDS Foundation

    lead OTHER

Principal Investigators

  • Barrot H Lambdin, PhD, MPH · Pangaea Global AIDS

  • Jessie Mbwambo, MD, PhD · Muhimbili University of Health and Allied Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-03-31
Completion
2017-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02167425 on ClinicalTrials.gov